Oxford Immunotec Announces that the Centers for Medicare and Medicaid Services (CMS) Increases Reimbursement for the T-SPOT®.TB Test CPT® Code 86481 Federal Supply Schedule (FSS) Contract Awarded to Oxford Diagnostic Laboratories for T-SPOT®.TB Testing Study Results Show Switching from the Tuberculin Skin Test (TST) to an Interferon Gamma Release Assay (IGRA) can Improve Healthcare Worker Test Adherence at a Lower Cost UK’s NICE Recommend replacing Mantoux with TB blood tests for Key Patient Groups AMA establishes a new CPT® Code for use with the T-SPOT®.TB test Oxford Immunotec announces US FDA approval of PMA supplement for the use of the T-Cell Xtend® reagent Independent study demonstrates that T-SPOT®.TB assay outperforms TST in predicting TB disease The T-SPOT®.TB Test Now Included in New CDC Guidelines Independent peer-reviewed study demonstrates that TB contact tracing based on use of the T-SPOT®.TB assay is more cost effective Oxford Immunotec Closes Second Tranche of $26 Million Series D Financing Led by New Leaf Venture Partners New study confirms 98.9% specificity of the T-SPOT®.TB assay Oxford Immunotec announces contract with Scancell Ltd to measure T cell response in Phase I/II clinical immunotherapy trial 2010 World TB Day T-SPOT.TB is first IGRA to be Approved for Sale in Taiwan 2009 World TB Day 46 Articles